Alimentary Pharmacology & Therapeutics最新文献_第7页

Letter: The Q425R Variant in Chronic Hepatitis Delta—Distinguishing Cirrhosis Prevalence From Portal Hypertension Severity 慢性肝炎的Q425R变异——区分肝硬化和门脉高压的严重程度

IF 7.6 1区医学

Alimentary Pharmacology & Therapeutics Pub Date : 2026-10-03 DOI: 10.1111/apt.71030

Dandan Weng, Pingping Zhang

引用次数: 0

Letter: Proton Pump Inhibitor Prescribing in Autoimmune Gastritis—From Real‐World Exposure to Indication‐Driven Reassessment. Authors' Reply 信函：自身免疫性胃炎的质子泵抑制剂处方——从现实世界暴露到指征驱动的重新评估。作者的回复

IF 7.6 1区医学

Alimentary Pharmacology & Therapeutics Pub Date : 2026-10-03 DOI: 10.1111/apt.71034

Sara Massironi, Marco Vincenzo Lenti, Edith Lahner, Antonio Di Sabatino, Silvio Danese

引用次数: 0

Editorial: When the Diagnosis is Uncertain, Can AI be Certain Enough? 社论：当诊断不确定时，人工智能能足够确定吗？

IF 7.6 1区医学

Alimentary Pharmacology & Therapeutics Pub Date : 2026-10-03 DOI: 10.1111/apt.71025

Rupa Banerjee, Nalini Raghunathan

引用次数: 0

Review Article: Beyond the Therapeutic Ceiling in Inflammatory Bowel Disease—Mechanism‐Based Positioning and Emerging Therapeutic Strategies 综述文章：炎症性肠病的治疗上限-基于机制的定位和新兴的治疗策略

IF 7.6 1区医学

Alimentary Pharmacology & Therapeutics Pub Date : 2026-10-03 DOI: 10.1111/apt.70978

Deloshaan Subhaharan, Sreedhar Subramanian

{"title":"Review Article: Beyond the Therapeutic Ceiling in Inflammatory Bowel Disease—Mechanism‐Based Positioning and Emerging Therapeutic Strategies","authors":"Deloshaan Subhaharan, Sreedhar Subramanian","doi":"10.1111/apt.70978","DOIUrl":"https://doi.org/10.1111/apt.70978","url":null,"abstract":"Background Therapeutic options for inflammatory bowel disease (IBD) have expanded rapidly with the introduction of selective interleukin (IL)‐23 inhibitors, Janus kinase inhibitors, sphingosine‐1‐phosphate receptor modulators, and several emerging therapeutic classes. Consequently, the major clinical challenge has shifted from developing effective therapies to determining how best to position them within increasingly complex treatment algorithms. Aims To review the contemporary and emerging therapeutic landscape in IBD, focusing on mechanism‐based treatment positioning, disease modification, refractory disease, and novel therapeutic strategies that may overcome the current therapeutic ceiling. Methods We performed a comprehensive review of PubMed, Ovid MEDLINE, Embase, and major international conference proceedings to identify pivotal clinical trials, long‐term extension studies, comparative effectiveness studies, real‐world evidence, and emerging therapeutic developments in IBD. Results Comparative studies have strengthened the positioning of selective iL‐23 inhibitors as foundational therapies in IBD, while oral small molecules continue to expand with novel mechanisms and improved convenience. Emerging strategies targeting TL1A, fibrosis and advanced combination therapy offer the potential to further improve outcomes, particularly in refractory disease. However, important challenges remain regarding optimal treatment sequencing, patient selection, long‐term safety and disease modification. Conclusion Contemporary IBD management is increasingly defined by mechanism‐based therapeutic positioning rather than simply expanding treatment options. Ongoing advances in comparative effectiveness research, novel therapeutic targets, and treatment strategies have the potential to further individualise care and improve long‐term patient outcomes.","PeriodicalId":121,"journal":{"name":"Alimentary Pharmacology & Therapeutics","volume":"11 1","pages":""},"PeriodicalIF":7.6,"publicationDate":"2026-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149086724","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Letter: P‐CAB Versus PPI for Antithrombotic Gastroprotection: The Importance of Longitudinal Treatment Dynamics—Authors' Reply 信函：P - CAB与PPI的抗血栓性胃保护作用：纵向治疗动态的重要性——作者回复

IF 7.6 1区医学

Alimentary Pharmacology & Therapeutics Pub Date : 2026-10-02 DOI: 10.1111/apt.71026

Min Joo Yoon, Soyoung Lee, Hye‐Kyung Jung, Min‐ho Kim, Suna Yu, Eui Sun Jeong, Chung Hyun Tae

引用次数: 0

Systematic Review: Inclusion of Patients With Difficult‐to‐Treat Inflammatory Bowel Disease in Randomized Controlled Trials of Advanced Therapies 系统评价：将难以治疗的炎症性肠病患者纳入先进疗法的随机对照试验

IF 7.6 1区医学

Alimentary Pharmacology & Therapeutics Pub Date : 2026-10-01 DOI: 10.1111/apt.70998

Tommaso Lorenzo Parigi, Virginia Solitano, Hailemichael Desalegn Mekonnen, Yuhong Yuan, Laurent Peyrin‐Biroulet, Vipul Jairath, Silvio Danese

{"title":"Systematic Review: Inclusion of Patients With Difficult‐to‐Treat Inflammatory Bowel Disease in Randomized Controlled Trials of Advanced Therapies","authors":"Tommaso Lorenzo Parigi, Virginia Solitano, Hailemichael Desalegn Mekonnen, Yuhong Yuan, Laurent Peyrin‐Biroulet, Vipul Jairath, Silvio Danese","doi":"10.1111/apt.70998","DOIUrl":"https://doi.org/10.1111/apt.70998","url":null,"abstract":"Background Criteria to define difficult‐to‐treat (DTT) inflammatory bowel disease (IBD) have recently been proposed, yet the inclusion and participation of patients with DTT‐IBD in randomized controlled trials (RCTs) are heterogeneous and poorly defined. Aims To explore inclusion and representation of patients with DTT‐IBD in RCTs. Methods We reviewed RCTs of advanced therapies (ATs) in ulcerative colitis (UC) and Crohn's disease (CD). DTT‐IBD was defined as active disease despite exposure to ATs with ≥ 2 different mechanisms of action. Secondary analyses assessed eligibility and participation of patients exposed to ≥ 1 or ≥ 2 ATs irrespective of mechanism of action, and in CD only, active disease after ≥ 2 intestinal resections and fistulizing disease. Results We included 179 RCTs, 93 in UC and 86 in CD, comprising 54,258 patients. In UC, 72% (67/93) of studies included patients with prior exposure to ATs and 16.1% (15/93) included participants exposed to agents with ≥ 2 mechanisms of action (DTT); among the 10 trials reporting patient‐level data, DTT‐UC accounted for 16.2% (814/5019). In CD, 73.3% (63/86) of RCTs included patients with prior exposure to ATs, and 10.5% (9/86) reported patients with DTT‐CD due to exposure to multiple classes of ATs. Patients with multifailure DTT‐CD accounted for 22.4% (773/3455) of the reported study populations. Subgroup‐specific efficacy outcomes for DTT‐IBD were not reported, except for one small trial that enrolled only DTT‐UC. Conclusions Few RCTs of advanced medications include patients with DTT‐IBD. In most trials, participants with DTT‐IBD represent a minority of the study population, and subgroup‐specific data are lacking.","PeriodicalId":121,"journal":{"name":"Alimentary Pharmacology & Therapeutics","volume":"481 1","pages":""},"PeriodicalIF":7.6,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149083799","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Clinical trial: The Effect on Intragastric pH and Pharmacokinetics of the PCAB Linaprazan Glurate in Healthy Subjects After Repeat‐Dose Administration for up to 14 Days 临床试验：重复给药长达14天后，PCAB谷氨酸利那普利赞对健康受试者胃内pH和药代动力学的影响

IF 7.6 1区医学

Alimentary Pharmacology & Therapeutics Pub Date : 2026-10-01 DOI: 10.1111/apt.70980

Kajsa Larsson, Kjell Andersson, Gunilla Huledal, Jouni Junnila, Kristofer Katkits Nilsson, Elham Yektaei, Matjaž Fležar, Peter Unge

{"title":"Clinical trial: The Effect on Intragastric pH and Pharmacokinetics of the PCAB Linaprazan Glurate in Healthy Subjects After Repeat‐Dose Administration for up to 14 Days","authors":"Kajsa Larsson, Kjell Andersson, Gunilla Huledal, Jouni Junnila, Kristofer Katkits Nilsson, Elham Yektaei, Matjaž Fležar, Peter Unge","doi":"10.1111/apt.70980","DOIUrl":"https://doi.org/10.1111/apt.70980","url":null,"abstract":"Background Linaprazan glurate (LG), a potassium‐competitive acid blocker (PCAB), has shown up to 100% and 93% 4‐week healing rates in a Phase 2 study in patients with LA grade A/B and C/D erosive oesophagitis, respectively. Aim To assess the Pharmacodynamic (PD) effect and Pharmacokinetics (PK) of multiple‐dose administration of LG. Methods In the open, randomised, parallel‐group, Phase 1 study, PD (intragastric pH) and PK were investigated after the first dose and 14 days of repeated administration of LG at dose levels 25, 50 and 75 mg q. d. and 25, 50 and 75 mg b.d. Results A total of 73 subjects were treated with LG during the study. After the first LG dose, pH > 4 was achieved within 60 and 10 min for the 50 mg b.d. and 75 mg b.d. dose groups, respectively. Dose–response was observed for HTRs at pH > 4, with > 90% for 50 mg b.d. and 75 mg b.d. on Day 1 and > 95% on Day 14. HTR was higher with 25 mg b.d. than with 50 mg q. d. both on Day 1 and Day 14. Mean AUC and mean C max for linaprazan, the main LG metabolite, increased approximately in proportion to dose with no apparent accumulation. Conclusions LG provided a rapid increase in gastric pH after the first dose, with an HTR pH > 4 close to 100% for dose levels 50 mg b.d. and 75 mg b.d. Linaprazan AUC and C max increased in proportion to LG dose. LG was safe and well tolerated at the studied dose levels.","PeriodicalId":121,"journal":{"name":"Alimentary Pharmacology & Therapeutics","volume":"167 1","pages":""},"PeriodicalIF":7.6,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149083793","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Letter: Sinonasal Microbiota: The Immunological Link Between Eosinophilic Oesophagitis and Chronic Rhinosunisitis? 鼻腔微生物群：嗜酸性粒细胞性食管炎和慢性鼻窦炎之间的免疫学联系？

IF 7.6 1区医学

Alimentary Pharmacology & Therapeutics Pub Date : 2026-10-01 DOI: 10.1111/apt.71027

William Fusco, Laura Bruno, Antonio Gasbarrini, Cristiano Caruso, Gianluca Ianiro

引用次数: 0

Letter: From Genetic Association to Clinical Prediction in Chronic Hepatitis D 信函：从遗传关联到慢性丁型肝炎的临床预测

IF 7.6 1区医学

Alimentary Pharmacology & Therapeutics Pub Date : 2026-10-01 DOI: 10.1111/apt.71029

Dandan Weng, Yingying Liu

引用次数: 0

Letter on: Pre-Emptive Initiation of Continuous Renal Replacement Therapy in Patients With Acute Liver Failure With Cerebral Edema Improves Outcomes: A Randomized Controlled Trial. Authors' Reply. 一项随机对照试验：对急性肝衰竭合并脑水肿患者进行持续肾脏替代治疗可改善预后。作者的回答。

IF 6.8 1区医学

Alimentary Pharmacology & Therapeutics Pub Date : 2026-10-01 Epub Date: 2026-08-01 DOI: 10.1111/apt.70889

Rakhi Maiwall, Meenu Bajpai, Samba Siva Rao Pasupuleti, Neha Chauhan, Mohit Prajapati, Manya Prasad, Prashant Agarwal, Rajendra Prasad Mathur, Sherin Thomas, Shiv Kumar Sarin

引用次数: 0